DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into
If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA European Commission
DUBLIN, Ireland , May 27, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines DUBLIN, Ireland , May 18, 2020 (GLOBE NEWSWIRE) -- Nabriva
-Cash runway extended into the fourth quarter of 2020 through judicious resource management- - XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Conference call today at
DUBLIN, Ireland , May 11, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
DUBLIN, Ireland , May 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial
Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP DUBLIN, Ireland , May 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development
DUBLIN, Ireland , April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medicaid
DUBLIN, Ireland , April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
